Last reviewed · How we verify
NCT05314868: Retro-C
Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery
trial testing PhotoFix in Congenital Heart Disease in 10 participants. Terminated before completion.
30 November 2022
Quick facts
| Lead sponsor | Artivion Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 31 March 2022 |
| Primary completion | 30 November 2022 |
| Estimated completion | 30 November 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PhotoFix
Conditions studied
- Congenital Heart Disease — all drugs for Congenital Heart Disease →
- Cardiac Anomaly — all drugs for Cardiac Anomaly →
Sponsor
Artivion Inc.
Who can join
Eligibility, any sex, with Congenital Heart Disease or Cardiac Anomaly. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this postmarket, retrospective, single center study is to evaluate the clinical outcomes of patients who have received PhotoFix® Decellularized Bovine Pericardium (PhotoFix) as a patch within a cardiac surgical repair or reconstruction procedure. PhotoFix is prepared from bovine pericardium, which is stabilized using a dye-mediated photo-oxidation process and sterilized using aseptic processing techniques.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05314868
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PhotoFix
Trials testing the same drug.
- NCT03669042 — Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery · NA · completed
Other recruiting trials for Congenital Heart Disease
Currently open trials in the same condition.
- NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
- NCT07023367 — Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents · NA · recruiting
- NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
- NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
- NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting
Other Artivion Inc. trials
Trials by the same sponsor.
- NCT05174767 — PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection · NA · active not recruiting
- NCT04142658 — PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban · Phase 3 · terminated
- NCT03669042 — Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05314868 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Artivion Inc.
- Last refreshed: 13 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05314868.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing